<code id='7CCF7265BD'></code><style id='7CCF7265BD'></style>
    • <acronym id='7CCF7265BD'></acronym>
      <center id='7CCF7265BD'><center id='7CCF7265BD'><tfoot id='7CCF7265BD'></tfoot></center><abbr id='7CCF7265BD'><dir id='7CCF7265BD'><tfoot id='7CCF7265BD'></tfoot><noframes id='7CCF7265BD'>

    • <optgroup id='7CCF7265BD'><strike id='7CCF7265BD'><sup id='7CCF7265BD'></sup></strike><code id='7CCF7265BD'></code></optgroup>
        1. <b id='7CCF7265BD'><label id='7CCF7265BD'><select id='7CCF7265BD'><dt id='7CCF7265BD'><span id='7CCF7265BD'></span></dt></select></label></b><u id='7CCF7265BD'></u>
          <i id='7CCF7265BD'><strike id='7CCF7265BD'><tt id='7CCF7265BD'><pre id='7CCF7265BD'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:fashion    Page View:4362

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In